- Trials with a EudraCT protocol (229)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
229 result(s) found for: Azoospermia.
Displaying page 1 of 12.
EudraCT Number: 2008-002362-66 | Sponsor Protocol Number: 111738 | Start Date*: 2008-09-03 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, observer-blind, multi-country, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals FLU NG vaccine compared to the referenc... | ||
Medical condition: Immunization against influenza in male and female subjects aged 66 years or older and 19-43 years of age. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-010811-34 | Sponsor Protocol Number: 113018 | Start Date*: 2009-04-16 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase III, open, non-randomized, multi-centric, single dose study to assess mmunogenicity and safety of Fluarix / Influsplit SSW® 2009/2010 injected intramuscularly in young adults (18 to 60 year... | ||
Medical condition: Immunization against influenza of healthy adults. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001310-24 | Sponsor Protocol Number: 111631 | Start Date*: 2008-05-30 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ / Influsplit SSW® 2008/2009 injected intramuscularly in young adults (18 to 60 ye... | ||
Medical condition: Immunization against influenza of healthy adults. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002360-33 | Sponsor Protocol Number: 111737 | Start Date*: 2008-08-27 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to ... | ||
Medical condition: Immunization against influenza in male and female subjects aged 18-41 years and 65 years or older. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) NL (Completed) DE (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-004711-35 | Sponsor Protocol Number: 112147 | Start Date*: 2008-10-07 |
Sponsor Name:GlaxoSmithKline S.A. | ||
Full Title: Estudio de vacunación, fase III, observador ciego, aleatorizado (3:3:2), control activo, multinacional, multicéntrico para evaluar la respuesta inmune celular y humoral de la vacuna FLU NG de GSK B... | ||
Medical condition: Inmunización frente a la gripe estacional de varones y mujeres de 65 años y mayores o de 18 a 40 años Immunization against seasonal influenza in men and woman aged 65 years and older or 18 to 40 y... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004455-29 | Sponsor Protocol Number: 112115 | Start Date*: 2008-12-05 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, randomized, multicentre, observer-blind study to compare and characterize the immunoginicity and safety parameters induced by various GSK Biologicals’ Adjuvant Systems in combination wi... | ||
Medical condition: Hepatitis B surface antigen (HBsAg) vaccine administred in HBV naïve adult subjects aged between 18 and 45 years old, inclusive, in good general health. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001445-26 | Sponsor Protocol Number: 110627 | Start Date*: 2008-05-30 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, randomized, observer blind, multi-centre study to evaluate the immunogenicity, safety and reactogenicity of study vaccine GSK1557482A (FluLaval thiomersal-free), Fluarix and FluLaval t... | ||
Medical condition: Immunization against influenza of healthy adults | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: EE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-001036-25 | Sponsor Protocol Number: UNI91103-201 | Start Date*: 2021-06-01 | |||||||||||
Sponsor Name:UNION therapeutics A/S | |||||||||||||
Full Title: A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UNI91103 INTRANASAL ADMINISTRATION IN ADULTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC COVID-19 | |||||||||||||
Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002992-33 | Sponsor Protocol Number: E7080-G000-304 | Start Date*: 2013-07-04 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular... | |||||||||||||
Medical condition: Unresectable Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002784-91 | Sponsor Protocol Number: HAW0501 | Start Date*: 2006-02-06 |
Sponsor Name:Cardiff and Vale NHS Trust | ||
Full Title: A Randomized, Multicentre, Parallel Group Single-Blind Study to Assess the Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily versus Divided Doses Three Times Dai... | ||
Medical condition: Ulcerative colitis is characterized by acute and chronic inflammatory changes to the mucosa and submucosa of the colon and rectum. Clinical presentations include increased stool frequency, bloody d... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-024283-18 | Sponsor Protocol Number: AF219-006 | Start Date*: 2011-05-20 | |||||||||||
Sponsor Name:Afferent Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects with Chronic Cough | |||||||||||||
Medical condition: Subjects with Chronic Cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003934-28 | Sponsor Protocol Number: SPON1455-15 | Start Date*: 2016-03-04 | |||||||||||
Sponsor Name:Cardiff University | |||||||||||||
Full Title: Enhanced Epidermal Antigen Specific Immunotherapy trial -1 (EE-ASI-1): A Phase 1a study of gold nanoparticles administered intradermally by microneedles to deliver immunotherapy with a proinsulin d... | |||||||||||||
Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003248-31 | Sponsor Protocol Number: 110806 | Start Date*: 2007-11-16 |
Sponsor Name:GSK Biologicals | ||
Full Title: An open, phase IV, non-randomised, single-centre study with two study groups to assess the immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals' combined reduced... | ||
Medical condition: Booster vaccination against diphtheria, tetanus and pertussis diseases in adults | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000316-31 | Sponsor Protocol Number: HIDR-0721/COV | Start Date*: 2021-07-15 |
Sponsor Name:FAES FARMA S.A. | ||
Full Title: Multicenter, double-blind, randomized clinical trial to evaluate the efficacy of calcifediol soft capsules versus placebo in reducing hospital admissions in patients with a positive diagnostic test... | ||
Medical condition: SARS-CoV-2 coronavirus infection (COVID-19). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-007876-41 | Sponsor Protocol Number: 111567 | Start Date*: 2008-03-07 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, randomized, open study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) when co-administered with GlaxoSmithKline Biologicals... | ||
Medical condition: Cervarix™ is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004134-26 | Sponsor Protocol Number: sof-crio | Start Date*: 2015-02-19 | ||||||||||||||||
Sponsor Name:Centro Masve -Università degli Studi di Firenze-AOUC | ||||||||||||||||||
Full Title: A MULTICENTER, PROSPECTIVE, SINGLE ARM, OPEN-LABEL, PILOT STUDY ON THE BENEFIT/COST/SAFETY PROFILE OF SOFOSBUVIR FOR SYMPTOMATIC MIXED CRYOGLOBULINEMIA | ||||||||||||||||||
Medical condition: HCV chronic hepatitis and Mixed Cryoglobulinemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005185-18 | Sponsor Protocol Number: HEPA-CRV431-207 | Start Date*: 2022-07-13 | |||||||||||
Sponsor Name:Hepion Pharmaceuticals, Inc. | |||||||||||||
Full Title: ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVAN... | |||||||||||||
Medical condition: NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016375-30 | Sponsor Protocol Number: MK-0462-086 | Start Date*: 2010-02-16 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura | |||||||||||||
Medical condition: Long term treatment of acute migraine, with or without aura, in children and adolescents, ages 12 to 17 years. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Prematurely Ended) EE (Completed) LV (Prematurely Ended) SE (Completed) FR (Prematurely Ended) PL (Prematurely Ended) DK (Completed) NO (Completed) GB (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004595-35 | Sponsor Protocol Number: BAY63-2521/17020 | Start Date*: 2014-09-11 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Multi-center phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult deltaF508 homozygous Cystic Fibrosis patients | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016374-32 | Sponsor Protocol Number: MK-0462-082 | Start Date*: 2010-02-15 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adole... | |||||||||||||
Medical condition: Acute treatment of migraine, with or without aura, in children and adolescents, ages 6 to 17 years, who do not have a satisfactory response to prior treatment with nonsteroidal anti-inflammatory dr... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) FI (Completed) BE (Completed) ES (Completed) EE (Completed) LV (Completed) SE (Completed) FR (Completed) DK (Completed) GB (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
